Mirati Therapeutics, Inc. (MRTX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in San Diego, CA, United States. Der aktuelle CEO ist Charles M. Baum.
MRTX hat IPO-Datum 2013-07-15, 587 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $4.12B.
Mirati Therapeutics, Inc. is an oncology company headquartered in San Diego, California, focused on developing targeted cancer treatments that address genetic and immunological drivers of the disease. The company's clinical pipeline includes MRTX849, a KRAS G12C inhibitor currently in Phase 1/2 trials for non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other malignancies, and Sitravatinib, a spectrum-selective kinase inhibitor in Phase 3 development for non-small cell lung cancer treatment. Mirati is also advancing a KRAS G12D inhibitor program in preclinical development and has established a collaboration with BeiGene, Ltd. for the development and commercialization of Sitravatinib. Founded in 1995, the company is dedicated to bringing precision oncology therapeutics to patients with difficult-to-treat cancers.
